Research and Development (R&D) at NT Pharma
Product research and development (R&D) is the driving force of NT Pharma’s long-term development, directed at new products in the fields of bone, joint, blood and liver diseases, tumors, the central nervous system, as well as other fields. NT Pharma’s R&D is market-oriented, focusing on unmet clinical needs, targeting product advantages in niche areas, and fully integrating social resources and in-depth cooperation with domestic and international R&D institutions
Technology Platform
Product Development Pipeline
Patients with low/intermediate risk myelodysplastic syndromes (MDS) currently do not have recommended therapeutic drugs in standard clinical guidelines; their therapy is primarily symptomatic treatment. NT Pharma R&D Project NT1101 is for the treatment of patients with low/intermediate risk MDS and is now at the Phase II clinical study stage.
Non-Alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) currently do not have approved therapeutic drugs. NT0801 demonstrated good anti-NAFLD effects in early animal-based experiments and is undergoing preclinical studies.
Project Code | Field | Project R&D Stage | Notes |
---|---|---|---|
NT1101 | Myelodysplastic syndromes | Phase II clinical study | |
NT0201 | Gliomatosis cerebri | Preclinical study | |
NT0801 | Non-Alcoholic Fatty Liver Disease | Preclinical study | |
NT1801 | Osteoporosis | Phase III clinical study | (United States) |
NT0401 | Schizophrenia | Human bioequivalence |

Intellectual property
Research Funding
Research on the addition of new indication - myelodysplastic syndromes for the recently developed Class I novel drug ‘Uroacitides Injection’ was awarded the thirteenth “Five-Year Plan” and obtained “significant drug discovery” project funding by China’s Ministry of Science in 2017
The Songzhi pill study for the treatment of hepatitis C won the “Ten-Year Plan” for major scientific and technological project. It was funded by China’s Ministry of Science in 2000. The study on the Songzhi pill for the treatment of viral hepatitis was initially funded by the National “863” project in 2003.
The NT0801 study for the treatment of non-alcoholic fatty liver disease was funded by the Hong Kong government in 2017